Aura Biosciences Future Growth
Future criteria checks 0/6
Aura Biosciences's earnings are forecast to decline at 8.2% per annum while its annual revenue is expected to grow at 65.9% per year. EPS is expected to decline by 1.4% per annum.
Key information
-8.2%
Earnings growth rate
-1.4%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 65.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
No updates
Recent updates
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 03Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Mar 28We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 01Aura gains as JMP starts with Bullish view citing treatment platform
Jul 19Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer
Jun 30Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Apr 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -143 | -125 | -121 | 3 |
12/31/2025 | N/A | -119 | -110 | -94 | 4 |
12/31/2024 | N/A | -102 | -97 | -86 | 5 |
12/31/2023 | N/A | -76 | -65 | -64 | N/A |
9/30/2023 | N/A | -71 | -65 | -64 | N/A |
6/30/2023 | N/A | -68 | -61 | -60 | N/A |
3/31/2023 | N/A | -63 | -56 | -56 | N/A |
12/31/2022 | N/A | -59 | -56 | -55 | N/A |
9/30/2022 | N/A | -55 | -50 | -49 | N/A |
6/30/2022 | N/A | -52 | -49 | -47 | N/A |
3/31/2022 | N/A | -51 | -45 | -42 | N/A |
12/31/2021 | N/A | -46 | -35 | -32 | N/A |
9/30/2021 | N/A | -40 | -26 | -24 | N/A |
6/30/2021 | N/A | -33 | -23 | -22 | N/A |
3/31/2021 | N/A | -29 | -22 | -21 | N/A |
12/31/2020 | N/A | -30 | -25 | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AURA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AURA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AURA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AURA is forecast to have no revenue next year.
High Growth Revenue: AURA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AURA's Return on Equity is forecast to be high in 3 years time